| Name : Mr | s. SANJU JHA (40 /F) | Date : 27/07/2024 | | | | |
|------------------------|---|---------------------------------|------------------------------------|--|--|--|
| Address : JA | /EST BENGAL, INDIA | | | | | |
| Examined by: | UHID : AMHL.0002392111 | | | | | |
| • | WHEEL - FULL BODY ANNUAL ALE HCK | PLUS CHECK ADVANCE | AHC No: AMHLAH212987 | | | |
| | | - Nil Significant | | | | |
| | PLAINTS | Musculoskeletal syst | em | | | |
| For corporate health o | checkup | Spine and joints | | | | |
| PRESENT KNOW | | - Nil Significant | | | | |
| No history of | - Diabetes mellitus, | Skin | | | | |
| | Hypertension, Dyslipidemia, Thyroid | - Nil Significant | | | | |
| | disorder, Heart disease, Stroke, Asthma | Past medical hi | - | | | |
| *_ | | Covid 19 | - Yes | | | |
| DRUG ALLE | RGY | Hospitalization for Covid 19 | - No | | | |
| NO KNOWN ALLERGY | :27/07/2024 | | | | | |
| SYSTEMIC REVIEW | | Personal histor | ry | | | |
| Π | | Marital status | - Married | | | |
| Cardiovascular syste | em | No. of children | - 2 | | | |
| - Nil Significant | | Diet | - Mixed Diet | | | |
| Respiratory system | | Alcohol Smoking | - does not consume alcohol - No | | | |
| - Nil Significant | | Chews tobacco | - No | | | |
| Oral and dental | | Physical activity | - Mild | | | |
| - Nil Significant | | t | | | | |
| - | | Family history | | | | |
| Gastrointestinal syst | em | Father | - has expired | | | |
| Nil Significant | | Mother | - has expired | | | |
| Genitourinary system | n | Diabetes Hypertension | - father,mother - father,mother | | | |
| - Nil Significant | | Coronary artery | - none | | | |
| Gynaec history | | disease | hene | | | |
| Last menstrual period | - 14.7.24; Periods - regular; | Cancer | - None | | | |
| | st child birth - 13 yrs; ginal delivery; Number of | PHYSICAL EXAMI | NATION | | | |
| abortions - 1 | | 📥 General | | | | |
| Central nervous syst | em | Build | - over weight | | | |
| - Nil Significant | | Height | - 163 | | | |
| Eyes | | Weight | - 68 | | | |
| - Nil Significant | | BMI Pallor | - 25.59 - No | | | |
| ENT | | Oedema | - NO - NO | | | |

: 27/07/2024

Date

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No : AMHLAH212987

Cardiovascular system

| Heart rate (Per minute) | - 72 |
|-------------------------|-------|
| Rhythm | - Re |
| | - B.F |

| Systolic(mm of Hg) | |
|---------------------|--|
| Diastolic(mm of Hg) | |
| Heart sounds | |

- Regular - B.P. Sitting - 121 - 77 - S1S2+

Respiratory system

| Breath sounds | - Normal vesicular breath |
|---------------|---------------------------|
| | sounds |
| | |

Abdomen

| Appearance | - Normal |
|--------------|----------|
| Organomegaly | - No |
| Tenderness | - No |

Opthalmology consultation

Opthalmology findings

- UCVA:RE:6/9 LE:6/9P NVA:RE:N8P LE:N8P OCULAR MOVEMENT: WNL ANT.SEG: WNL ACCPT:SPECTACLE PWR RE:+0.50DS(6/6) LE:+0.75/-1.25X155*(6/6) ADD(BE):+1.00DSPH (N6) ADVICE:*Glass Rx.*Review after 1yr/SOS

Printed By : Benazir Begaum

: 27/07/2024

Date

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No : AMHLAH212987

| COMPLETE HAEMOGRAM PROFILE | | | | | | | |
|--|---------------------|----------------|--------|------------|--|--|--|
| Test Name | Result | Unit I | Level | Range | | | |
| Hemoglobin | 9.9 * | g/dl | • | 12.0-15.0 | | | |
| RBC COUNT | 4.13 | Million/ ul | • | 3.8-4.8 | | | |
| Hematocrit - Hct: | 30.5 * | % | • | 36-46 | | | |
| MCV | 73.7 * | fl | • | 83-101 | | | |
| MCH | 24.0 * | pg | • | 27-32 | | | |
| MCHC | 32.6 | % | • | 31.5-34.5 | | | |
| RDW | 16.8 * | % | • | 11.8-14.0 | | | |
| WBC Count | 8600 | /cu mm | | 4000-10000 | | | |
| Platelet Count | 1.59 | lacs/cu mm | • | 1.5-4.0 | | | |
| Neutrophils | 73 | % | • | 40-80 | | | |
| Lymphocytes | 19 * | % | • | 20-40 | | | |
| Monocytes | 05 | % | • | 2-10 | | | |
| Eosinophils | 03 | % | • | 01-06 | | | |
| Basophils | 00 | % | • | 0-0 | | | |
| RBC: | Anisocyt Hypochr | | icrocy | tic | | | |
| Platelets: | Adequat | e. | | | | | |
| ERYTHROCYTE SEDIMENTATION RATE (ESR) | 55 * | mm/1st hr | • | 0-20 | | | |

URINE ROUTINE AND MICROSCOPY

| Test Name | Result | Unit | Level | Range | | |
|------------------|--------------|--------------|-------|-------|--|--|
| Volume: | 40 | mL | | | | |
| Colour: | Pale Stra | aw | | | | |
| Appearance | Turbid | | | | | |
| Specific Gravity | 1.010 | | | | | |
| pH: | 6.0 | | | | | |
| Albumin: | Not Dete | ected | | | | |
| Glucose | Not Detected | | | | | |
| Ketone: | Not Dete | Not Detected | | | | |
| Bile Pigments | Not Dete | ected | | | | |
| RBC | Nil | /hpf | | | | |
| Pus Cells | 1-2 | /hpf | | | | |

| Epithelial Cells | 2-4 /h.p | .f /hpf | | |
|---|-------------------------|---------|-------|---------|
| Casts: | Not Fou | und | | |
| Crystals: | Not Found | | | |
| URINE SUGAR- FAST Test Name URINE GLUCOSE(FASTING) | ING(QU Result Nil | | | Range |
| BLOOD GROUPING A | | PING (A | ABO A | ND RH) |
| Test Name ABO Group: | | Unit | | Range |
| Rh (D) Type: | POSITI | VE | | |
| LIVER FUNCTION TES | ST (PAC | KAGE |) | |
| Test Name | Result | | Level | Range |
| ALT(SGPT) - SERUM | 28 | U/L | • | 0-35 |
| ALBUMIN - SERUM | 4.7 | g/dL | • | 3.5-5.1 |
| ALKALINE PHOSPHATASE - SERUM | 97 | U/L | • | 33-98 |
| AST (SGOT) - SERUM | 26 | U/L | • | 0-35 |
| BILIRUBIN TOTAL - SERUM | 0.7 | mg/dl | ∟ ● | 0.3-1.2 |
| LIPID PROFILE TEST | (PACKA | AGE) | | |
| Test Name | Result | Unit | Level | Range |
| CHOLESTEROL - SERUM | 176 | mg/dl | | 0-200 |
| Non-HDL Cholesterol | 139 | | | |
| CREATININE - SERUN | 1 | | | |
| Test Name | Result | Unit | Level | Range |
| CREATININE - SERUM | 0.6 | mg/dl | | 0.6-1.1 |
| LIVER FUNCTION TES | ST (PAC | KAGE |) | |
| Test Name | Result | Unit | Level | Range |
| GGTP: GAMMA GLUTAMYL TRANSPEPTIDASE - SERUM | 22 | U/L | • | 0-38 |
| | | | | |

Witl

Within Normal Range

Borderline High/Low

Out of Range

Date : 27/07/2024

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No : AMHLAH212987

| | (FASTIN | NG) | | | TRIGLYCERIDES - SERUM | 98 | mg/dl | - | 0-150 |
|--|---------------|----------------|--------|------------------------------|---|--------------|---------|----------|-----------|
| Test Name | Result | Unit | Level | Range | | | | | |
| GLUCOSE - PLASMA | 93 | mg/dl | • | 70-99 | THYROID PROFILE - | I(T3,T4 / | AND T | SH) | |
| (FASTING) | | | | | Test Name | Result | Unit | Level | Range |
| HBA1C (GLYCOSYLA HAEMOGLOBIN)-WHO | | | | | TSH: THYROID STIMULATING | 3.15 | µIU/m | nL 🔍 | 0.38-5.33 |
| Test Name | Result | | l evel | Range | HORMONE - SERUM | | | | |
| HBA1C | 5.3 | % | | Nondiadetic : 4 | URIC ACID - SERUM | | | | |
| (GLYCOSYLATED | 0.0 | 70 | | - 5.6 % | Test Name | Result | Unit | Level | Range |
| HAEMOGLOBIN)-WHO LE BLOOD | | | | Prediabetics : 5.7 - 6.4% | URIC ACID - SERUM | 5.4 | mg/dl | | 2.4-5.7 |
| | | | | Diabetes : | LIVER FUNCTION TE | EST (PAC | KAGE |) | |
| | | | | >/= 6.5% ADA | Test Name | • | | • | Range |
| | | | | Theraputic goal | BILIRUBIN | 0.1 | mg/dl | _ | 0.0-0.2 |
| | | | | : <7% | CONJUGATED (DIRECT) - SERUM | 0.1 | | | 0.0-0.2 |
| LIPID PROFILE TEST | (PACKA | AGE) | | | | | | | |
| Test Name | Result | Unit | Level | Range | BUN (BLOOD UREA | NITROG | EN) | | |
| HDL CHOLESTEROL - | 37 | mg/dl | _ ● | 30-70 | Test Name | Result | Unit | Level | Range |
| SERUM | | | | | BUN (BLOOD UREA NITROGEN) | 7.7 | mg/dl | - | 7.0-18.0 |
| LDL CHOLESTEROL | 124 * | mg/dl | _ ● | 0-100 | | | | | |
| -SERUM | | | | | LIVER FUNCTION TE | - | | - | _ |
| VLDL CHOLESTEROL - | 15 | mg/dl | _ ● | 0-35 | Test Name | | Unit | Level | Range |
| SERUM (Calculated) | | | | | A/G - RATIO | 1.3 | | • | 1.0-2.0 |
| LIVER FUNCTION TES | ST (PAC | KAGE |) | | BUN/CREATININE R | ΔΤΙΟ | | | |
| Test Name | Result | | | Range | Test Name | Result | Unit | Level | Range |
| PROTEIN TOTAL - SERUM | 8.3 | g/dL | • | 6.4-8.3 | BUN/CREATININE RATIO | 12.8 | • | | |
| | 2.0 | g/dL | • | 1.8-3.6 | ivino - | | | | |
| GLOBULIN: (CALCULATED) - SERUM | 3.6 | g/uL | | 1.8-3.0 | PAP SMEAR /CERVICA | AL SMEAF | २ | | |
| | | | | | Ref No: | | | | |
| | (T3,T4 / | AND T | SH) | | AG01.C2406151 SPECIMEN TYPE: | | | | |
| THYROID PROFILE - I | Result | Unit | Level | Range | Conventional cervical | smear (P: | apanico | laou st | ain) x 1 |
| THYROID PROFILE - I Test Name | | | | 0.87-1.78 | SPECIMEN ADEQUA | - | apamoo | | |
| THYROID PROFILE - I Test Name TOTAL T3: TRI IODOTHYRONINE - SERUM | 1.74 | ng/ml | | | Satisfactory for evalua | tion with e | endoce | rvical c | ells. |
| Test Name TOTAL T3: TRI IODOTHYRONINE - | | ng/ml | | | Satisfactory for evalua | ition with e | | | |
| Test Name TOTAL T3: TRI IODOTHYRONINE - SERUM | 1.74 | - | | | Satisfactory for evalua INTERPRETATION/RI Negative for intraepith | ition with e | | | |
| Test Name TOTAL T3: TRI IODOTHYRONINE - | | ng/ml μg/dL | | 5.48-14.28 | Satisfactory for evalua INTERPRETATION/RI Negative for intraepith organism | ition with e | | | |
| Test Name TOTAL T3: TRI IODOTHYRONINE - SERUM TOTAL T4: THYROXINE - SERUM | 1.74 12.01 | μg/dL | | | Satisfactory for evalua INTERPRETATION/RI Negative for intraepith | ition with e | | | |
| Test Name TOTAL T3: TRI IODOTHYRONINE - SERUM TOTAL T4: | 1.74 12.01 | μg/dL | | | Satisfactory for evalua INTERPRETATION/RI Negative for intraepith organism | ition with e | | | |

UHID : AMHL.0002392111

Date : 27/07/2024

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No : AMHLAH212987

TREADMILL TEST / STRESS TEST

STRESS TEST IS NEGATIVE FOR PROVOCABLE MYOCARDIAL ISCHAEMIA.

X-RAY CHEST PA

Descriptive.

Dr. ARKADEEP DEY DNB RESIDENT In consultation with

Dr. KHWAJA KAMRUDDIN DMRD DNB RESIDENT Reg. No. 62704 (WBMC)

X-RAY MAMMOGRAPHY BILATERAL (MHC)

Requires additional evaluation, 1

INVESTIGATIONS NOT DONE / NOT YET REPORTED / NOT PART OF PACKAGE(LAB,RADIOLOGY & CARDIOLOGY)

Haematology

URINE SUGAR - POST PRANDIAL (QUALITATIVE)

Biochemistry

GLUCOSE - PLASMA (POST PRANDIAL)

Ultrasound Radiology ULTRASOUND SCREENING WHOLE ABDOMEN





Date : 27/07/2024

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No : AMHLAH212987

Printed By :

AHC Physician / Consultant Internal Medicine

Note :- The Health Check-up examinations and routine investigations have certain limitations and may not be able to detect all the diseases. Any new or persisting symptoms should be brought to the attention of the Consulting Physician. Additional tests, consultations and follow up may be required in some cases. Name : Mrs. SANJU JHA (40 /F)

: 27/07/2024

Date

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No : AMHLAH212987

| AICVD RISK SCORE REPORT | | | | | |
|-------------------------|------------|------------------|--|--|--|
| RISK STATUS | YOUR SCORE | ACCEPTABLE SCORE | | | |
| Low Risk | 2 | 3 | | | |

Your cardiovascular disease risk in the next 10 years is within the Normal limits for your age and gender

The AICVD risk score developed by Apollo Hospitals is a novel artificial intelligence -based risk scoring system that predicts your risk of having Coronary Artery Disease (CAD) related events in the next ten years. This scoring system uses Indian data and has been validated by multiple national and international institutions. This risk score is more than 92% accurate and has been compiled based on your physical parameters, heart health attributes, lifestyle and medical history. **Note:** The risk category is determined through the ratio between guest score and acceptable score at multiple decimal points. The outputs are shown in whole numbers.

Based on your AICVD risk score you are advised the following:

- Follow the guidance and education on lifestyle and dietary management provided through the ProHealth program. Maintain a healthy BMI (<25). Avoid tobacco in any form and if you are a smoker, stop smoking.
- Continue with medications for high blood pressure, diabetes, or dyslipidemia, if advised by your physician. Maintain HbA1c <7% (<53mmol/mol), blood pressure <140/90mmHg.
- Follow your physician's advice regarding follow up tests, consults and annual health assessment

DISCLAIMER

- 1. This is not a diagnostic tool and it does not guarantee accuracy of the result and cannot be acted upon independently.
- 2. This risk score and clinical algorithm is a general guideline for physicians. Any additional laboratory investigations, diagnostic imaging, treatment or patient education related to lifestyle management is under the physician's or cardiologist's discretion.
- 3. To ensure the information in the report is up to date, accurate and correct, doctor shall be consulted for interpretation of the report.
- 4. Apollo Hospitals and its staff does not offer any assurance on the information made available or be liable for any loss or damage as the said report is based on the AICVD risk score without any intervention from their side .
- 5. By usage of the AICVD risk score, it is deemed that the beneficiary of this service has agreed to get the same done at his own risk and further agrees with this disclaimer without any limitation or any clauses or sub-clauses.

The Clinical AI Models and APIs used at Apollo Hospitals are certified by ISO 13485 : 2016 vide certificate no. MD 763515